[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509714":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":32,"responsibleParty":47,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Next Biomedical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Transcatheter Arterial Micro-Embolization","EXPERIMENTAL","If abnormal blood vessels related to pain are identified by angiography, selective embolization is performed using Nexsphere-F.",[13],"Device: Transcatheter Arterial Micro-Embolization",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Participants will undergo TAME with Nexsphere-F.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Hyuckmin Kwon","Severance Hospital","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","+82-32-454-4800","next@nextbiomedical.co.kr",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":29},"Sungmo Moon",[33],{"facility":23,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":19,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Seoul","Seodaemun-gu","03722","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},[46],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100509714","transcatheter-arterial-micro-embolization-tame-using-nexsphere-f-in-patients-with-knee-degenerative-osteoarthritis-100509714",false,"NCT05917028","Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis","A Single Arm, Single Center, Open Label , Pilot Clinical Study to Evaluate the Efficacy and Safety of Transcatheter Arterial Micro Embolization (TAME) Using Nexsphere F in Patients With Knee Degenerative Osteoarthritis","Inclusion Criteria:\n\n* Those who fall under Kellgren-Lawrence grade 2 to 3 according to the criteria in accordance with ACR guidelines and X-ray findings used within 12 months\n* VAS score exceeding 50mm\n* An adult male and female over 50 years of age\n* Preservative therapy Glucosamine chondroitin sulfate\u002Fphysiological therapy and rehabilitation exercises, and joint injections of hyaluronic acid for more than 12 weeks\n* A person who agrees to maintain existing medication treatments during the clinical trial period but does not receive additional medication or new conservative treatments for knee osteoarthritis pain management.\n\nExclusion Criteria:\n\n* A locally infected patient\n* A person whose life expectancy is less than six months\n* A person with symptoms of lower extremities that are considered secondary to atherosclerosis or arterial vascular disease (ex: claudication ischemic rest pain)\n* A person diagnosed with rheumatism or infectious arthritis\n* A person who has undergone knee arthroplasty\n* A person who has not had knee microfracture surgery for more than 10 years\n* INR 2.5 or less than 30,000 platelets\n* Anaphylaxis-causing iodine allergy\n* Patients with renal dysfunction or impaired renal function who have been diagnosed with less than 45 GFR (eGFR) within the last 60 days\n* Those who have a taboo on MR videos\n* Pregnant women\n* Other cases where it is deemed inappropriate to participate in this clinical trial at the discretion of the researcher","ALL","50 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"NA","Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the therapeutic effect and safety of Nexsphere-F embolization for patients who need additional treatment because pain is not controlled even if conventional treatments are taken.",[66],"Osteoarthritis","2025-03-27",{"date":69,"type":70},"2025-04-02","ACTUAL",{"date":72,"type":70},"2023-10-23",{"date":74,"type":60},"2025-12",{"name":5,"class":6},1]